Melanoma - Pipeline Review, H1 2020

May 2020 | 999 pages | ID: M440B923728EN
Global Markets Direct

Abstracts

Melanoma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma – Pipeline Review, H1 2020, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 24, 173, 192, 2, 19, 267, 32 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 25, 21, 83 and 11 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Melanoma - Overview
Melanoma - Therapeutics Development
Melanoma - Therapeutics Assessment
Melanoma - Companies Involved in Therapeutics Development
Melanoma - Drug Profiles
Melanoma - Dormant Projects
Melanoma - Discontinued Products
Melanoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Melanoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
Melanoma - Pipeline by 4D Pharma Plc, H1 2020
Melanoma - Pipeline by 4SC AG, H1 2020
Melanoma - Pipeline by 7 Hills Pharma LLC, H1 2020
Melanoma - Pipeline by AbbVie Inc, H1 2020
Melanoma - Pipeline by Abcuro Inc, H1 2020
Melanoma - Pipeline by Abion Inc, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Melanoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4D Pharma Plc
4SC AG
7 Hills Pharma LLC
AbbVie Inc
Abcuro Inc
Abion Inc
Abivax SA
ABM Therapeutics Inc
AC Bioscience SA
Acepodia Biotech Inc
ACF Pharmaceuticals LLC
Achilles Therapeutics Ltd
Actym Therapeutics Inc
Adaptimmune Therapeutics Plc
Adare Pharmaceuticals Inc
ADC Therapeutics SA
Adicet Bio Inc
Adjuvance Technologies Inc
Aduro BioTech Inc
Advanced BioDesign
Advanced Cancer Therapeutics LLC
Advantageous Systems LLC
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Afecta Pharmaceuticals Inc
Affichem SA
AgenTus Therapeutics Inc
Agenus Inc
AGV Discovery SAS
AIM ImmunoTech Inc
AIMM Therapeutics BV
AiVita Biomedical Inc
Akeso Inc
Alkermes Plc
Allergy Therapeutics Plc
Alligator Bioscience AB
AlphaMab Co Ltd
Alphamab Oncology
ALS Biopharma LLC
Altor Bioscience LLC
Amgen Inc
Anaveon AG
Andes Biotechnologies
AnGes Inc
Antengene Corp
Antibe Therapeutics Inc
AntiCancer Inc
APEIRON Biologics AG
Apexian Pharmaceuticals Inc
Apexigen Inc
Aphios Corp
APO-T BV
Apogenix AG
Apollomics Inc
Aposense Ltd
Arcus Biosciences Inc
Arisaph Pharmaceuticals Inc
Asana BioSciences LLC
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
AstraZeneca Plc
Athenex Inc
Atreca Inc
aTyr Pharma Inc
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
Avalia Immunotherapies Ltd
AVAX Technologies Inc
Avidin Ltd
Bantam Pharmaceutical LLC
Barricade Therapeutics Corp
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Bayer AG
BeiGene Ltd
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Neoantigen Biotechnology Co Ltd
BerGenBio ASA
Bessor Pharma LLC
Binjiang Pharma, Inc.
Bio-Cancer Treatment International Ltd
Bio-Thera Solutions Ltd
BioAtla LLC
Biocad
Biogazelle NV
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
BioInvent International AB
BioLineRx Ltd
BioMed Valley Discoveries Inc
Bionomics Ltd
BioNTech SE
Bioquark Inc
Biosion Inc
Biothera Pharmaceutical Inc
BioVaxys LLC
Biovista Inc
BioXcel Therapeutics Inc
BJ Bioscience Inc
Boehringer Ingelheim International GmbH
Boston Biomedical Inc
BriaCell Therapeutics Corp
BridgeBio Pharma Inc
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Bromodomain Pharmaceuticals Inc
Byondis BV
Calidi Biotherapeutics Inc
Calithera Biosciences Inc
Can-Fite BioPharma Ltd
Cancure Ltd
Cantargia AB
CDG Therapeutics Inc
CDR-Life Inc
Celdara Medical LLC
Celldex Therapeutics Inc
Cellestia Biotech AG
Cellid Co Ltd
Celprogen Inc
Centurion BioPharma Corp
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Chineo Med Beijing Co Ltd
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co Ltd
Cloaked Therapeutics LLC
Codagenix Inc
CohBar Inc
Constellation Pharmaceuticals Inc
Convalife
Corvus Pharmaceuticals Inc